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Abstract
Endometriosis is a common chronic inflammatory condition in which endometrial tissue appears outside the uterine cavity.
Because ectopic endometriosis cells express both estrogen and progesterone (P4) receptors, they grow and undergo cyclic
proliferation and breakdown similar to the endometrium. This debilitating gynecological disease affects up to 15% of reproduc-
tive aged women. Despite many years of research, the etiopathogenesis of endometrial lesions remains unclear. Retrograde
transport of the viable menstrual endometrial cells with retained ability for attachment within the pelvic cavity, proliferation,
differentiation and subsequent invasion into the surrounding tissue constitutes the rationale for widely accepted implantation
theory. Accordingly, the most abundant cells in the endometrium are endometrial stromal cells (EnSCs). These cells constitute a
particular population with clonogenic activity that resembles properties of mesenchymal stem/stromal cells (MSCs). Thus, a
significant role of stem cell-based dysfunction in formation of the initial endometrial lesions is suspected. There is increasing
evidence that the role of epigenetic mechanisms and processes in endometriosis have been underestimated. The importance of
excess estrogen exposure and P4 resistance in epigenetic homeostasis failure in the endometrial/endometriotic tissue are crucial.
Epigenetic alterations regarding transcription factors of estrogen and P4 signaling pathways in MSCs are robust in endometriotic
tissue. Thus, perspectives for the future may includeMSCs and EnSCs as the targets of epigenetic therapies in the prevention and
treatment of endometriosis. Here, we reviewed the current known changes in the epigenetic background of EnSCs andMSCs due
to estrogen/P4 imbalances in the context of etiopathogenesis of endometriosis.
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Introductory Overview
Endometriosis – Disorder Characteristics and
Pathogenesis Theories
The term “endometriosis” refers to a condition in which en-
dometrial tissue appears outside the uterine cavity [1].
Endometriosis can be either endopelvic or extrapelvic, de-
pending on the location of endometrial tissue implantation.
Abnormally located endometrial foci are primarily found in
the pelvis, including ovaries, ovarian fossa, fallopian tubes,
uterine wall (endometriosis interna or adenomyosis), broad
ligaments, round ligaments, uterosacral ligaments, appendix,
large bowel, ureters, bladder or rectovaginal septum [2, 3].
Extrapelvic locations of endometriosis are rare. However, sev-
eral cases of endometriosis of upper abdomen, abdominal
wall, abdominal scar tissue, diaphragm, pleura, pericardium,
liver, pancreas, lower and upper respiratory tract tissue or even
brain have been reported in the literature [3–6].
The tissue within the ectopic endometrium is biologically
the same as basal intrauterine endometrial tissue, consisting of
stroma cells, glands and smooth muscles [7]. The tissue is
innervated and vascularized, including both blood and lym-
phatic networks [7, 8].
Because endometriosis cells express estrogen receptors
(ERα, ERβ and GPER) and P4 receptors (PR-A and PR-B),
they grow and undergo cyclic proliferation and breakdown
similar to the endometrium [9, 10]. Local inflammatory reac-
tions potentially caused by the bleedings may predispose to
the occurrence of pain and more serious complications related
to fibrosis, scar tissue formation and adhesions during repair
processes [1, 11]. However, despite of the evidence for a re-
lationship between endometriosis and inflammation, it is not
clear whether the inflammatory process favors the develop-
ment of endometriosis foci or the endometriosis foci induce
the inflammatory process [12–14]. In the majority of endome-
triosis cases, pelvic pain, especially associated with menstru-
ation, significantly compromises the quality of life of affected
women [15]. Moreover, in addition to pain-related dysmenor-
rhea and dyspareunia, endometriosis reduces the ability to get
pregnant and to have a successful pregnancy outcome [16]. It
has also been observed that women with endometriosis have a
higher incidence of cancer and autoimmune diseases [13, 17].
Endometriosis is a multifactorial disease with the involve-
ment of genetic, immunological, hormonal, anatomical and
environmental factors in different proportions [12–14]. The
immune system is responsible for eliminating cells that are
located in ectopic sites, and the failure of this elimination in
endometriosis is due either to resistance of endometriotic cells
to be eliminated by immune cells or to a deficit in the immune
response [13, 18]. Endometriosis is known as an estrogen-
dependent and P4-resistant process [19]. Numerous studies
have shown that endometriosis is associated with aberrant
growth and loss of sensitivity to apoptosis of endometrial
tissue cells. Factors contributing to apoptosis resistance in-
clude increased expression of anti-apoptotic proteins, such
as Bcl-2, c-IAP1, and c-IAP2, in ectopic endometrial cells
compared to eutopic endometrial cells [20], which may ex-
plain their survival in ectopic foci and their resistance to elim-
ination by apoptosis-inducing processes or by immune cells.
The activating effect of estrogen on endometriotic cells may
cause the anti-apoptotic status of these cells [21]. There are
two types of endometriotic cells, namely epithelial and stro-
mal, and the reported alterations tend to affect both cell types.
It is not possible to affirm whether these alterations are intrin-
sic to the endometriotic cells or induced by their ectopic loca-
tion [21].
Despite several decades of intensive investigation into
the underlying etiology and pathogenesis of endometri-
osis, the current understanding of the disease remains un-
clear. Several theories for the pathogenesis of endometri-
osis have been elaborated or updated in recent years, in-
cluding implantation and metaplasia of Müllerian-type ep-
ithelium (coelomic metaplasia) theories as well as the in-
duction theory (a combination of the previous two theo-
ries) that assumes the influence of unidentified substances
released from shed endometrium inducing formation of
endometriotic tissue from undifferentiated mesenchyme
[12, 22]. It has been recently proposed that endometriosis
develops from stem cells derived from bone marrow,
which would also explain extraperitoneal endometriosis
lesions [23, 24].
Retrograde transport of viable menstrual endometrial
cells with retained ability to attach within the pelvic cavity
(initially to the peritoneum), proliferate, differentiate and
invade into surrounding tissue constitutes the rationale for
the most widely accepted implantation theory. According to
this theory, endometrial cells may also spread out through
the lymphatic and/or the vascular system, resulting in for-
mation of endometrial foci in more distant locations [18,
22]. In addition, evidence that the endometrium contains a
particular population of cells with clonogenic activity that
resembles properties of mesenchymal stem cells (MSCs),
may shed new light on the implantation theory, suggesting
a significant role of stem cell-based dysfunction in forma-
tion of the initial endometrial lesions [25, 26]. Some endo-
metrial cell dysfunction may explain why the retrograde
menstruation process frequently observed in healthy wom-
en is not associated with endometriosis initiation [27].
Theories on the pathogenesis of endometriosis related to
stem cells are presented in Fig. 1.
Similar to the pathogenesis, considerable controversy
remains regarding the prevalence, natural history and op-
timal treatment of endometriosis [16, 22, 28–30]. It is
generally accepted that approximately 10% (range of 5
to 15%) of reproductive aged women suffer from
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endometriosis, whereas significantly higher percentages
of endometriosis-related treatments (25 to 50%) have been
administered amongst infertile female patients [28–30].
Moreover, the prevalence of endometriosis may be influ-
enced by race/ethnicity [31].
Endometrial Stem Cells
Endometrial/Decidual Stromal Cells
The most abundant cells in the human endometrium are endo-
metrial stromal cells (EnSCs). During the secretory phase of the
menstrual cycle, especially if pregnancy occurs, EnSCs or their
equivalents in the decidua, i.e., decidual stromal cells (DSCs), are
differentiated (decidualized) by the effect of P4 and other hor-
mones. During this process, EnSCs or DSCs increase in size and
change in shape from a fibroblastic appearance to a rounder
morphology. Decidualized cells produce prolactin (PRL),
insulin-like growth factor binding protein-1 (IGFBP-1) and other
factors, such as IL15 [32]. Some authors consider EnSCs as
precursor undifferentiated cells and DSCs as decidualized cells
[33], thus creating confusion. Because the decidualization pro-
cess occurs in both the decidua and the non-pregnant
endometrium, there are precursor cells and decidualized cells in
both tissues. The origin of EnSCs and DSCs as well as their
cellular lineage ascriptions were unknown until recently. We
isolated human EnSCs and DSCs, and we grew them in culture,
establishing different cell lines that allowed us to identify the
antigenic phenotype of these cells, define their functions and
establish their origin and lineage (Table 1) [34, 37, 41, 51–53].
Several groups have demonstrated in humans and mice that
EnSCs and DSCs show immunological activities [34, 41,
53–55], suggesting that these cells may have a relevant role in
the immunological interrelationship between the mother and fe-
tus as well as in maternal–fetal tolerance (Table 1). In addition to
the finding that EnSCs and DSCs are the same cell in two dif-
ferent physiological situations (non-gestation and gestation, re-
spectively), it has been observed that DSCs are more responsive
to decidualization, suggesting that the pregnancy environment
enhances the capacity of stromal cells to decidualize [34].
Interestingly, this progression is blocked in endometriotic cells
[23]. Stromal cells in endometriosis foci (eEnSCs) show an an-
tigen phenotype equivalent to that of EnSCs and DSCs, but they
do not fully decidualize [21]. During decidualization, EnSCs and
DSCs undergo apoptosis [56], but eEnSCs are resistant to cell
death [20].
Fig. 1 Theories on the pathogenesis of endometriosis related to stem
cells. Endometrial stem cells related pathway marked in yellow. (EER –
embryonic epithelial remnants; BMSCs – bone marrow stem/progenitor
cells; EnSCs – endometrial stromal cells). A. Endometriosis may origi-
nate from the metaplasia of EER (e.g., from embryonic mullerian system)
that are present in the mesothelial lining of the visceral and abdominal
peritoneum; B. BMSCs could disseminate to ectopic sites via hematoge-
nous and lymphatic spread (hematogenous or lymphatic metastases, re-
spectively), accounting for the presence of endometriosis lesions in
distant sites outside the pelvis, including the brain, lung, lymph nodes,
extremities, spine and the abdominal wall; C. In retrograde
(retroperitoneal) menstruation, menstrual blood containing EnSCs de-
rived from BMSCs flows back through the fallopian tubes and into the
pelvic cavity. This endometrial reflux is commonly observed during men-
struation, but in certain conditions of defective cellular immunity EnSCs
may implant and proliferate. In addition to implantation theory, hemato-
poietic and lymphatic dissemination of EnSCs is proposed
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Endometrial/Decidual Stromal Cells and Mesenchymal
Stem/Stromal Cells
Based on the expression of STRO-1, a MSC marker, by
DSCs, one of us (EGO) was the first to propose the relation-
ship between DSCs and mesenchymal stem/stromal cells
(MSCs) [52]. This possibility was subsequently confirmed
by other groups for DSCs and EnSCs [35, 36]. In our experi-
ence, the phenotype and functionality of EnSC and DSC lines
are identical. It has been observed that these cells express
MSC-associated antigens and stem cell markers (OCT-4,
NANOG and ABCG2), and under appropriate culture condi-
tions, they have the ability to differentiate into osteoblasts,
chondrocytes and adipocytes, indicating that EnSCs and
DSCs are closely related to or derived from MSCs [35, 36,
38]. In the case of EnSCs, this possibility has been confirmed
in women who have received a bone marrow transplant be-
cause donor cells (both stromal and epithelial cells) have been
detected in their endometrium [57]. Precursors of DSCs and
EnSCs (preDSCs and preEnScs) also correspond to MSCs in
the human endometrium (endometrial MSCs, eMSCs) as
reported by other authors, i.e., clonogenic, self-renewing,
multipotent cells that can differentiate into adipogenic, osteo-
genic, chondrogenic and myogenic lineages. Similar to
preDSCs and preEnSCs, eMSCs are CD146+, CD140b+
and SUSD2+, and they decidualize, are found in perivascular
sites and have also been associated with pericytes [34, 37, 58].
MSCs may migrate from bone marrow to different tissues to
give rise to different mesenchymal lineages as follows: fibro-
blasts, adipocytes, osteoblasts and myofibroblasts as well as
EnSCs and DSCs in the uterus. Logically, cells derived from
this same precursor share a number of common morphologi-
cal, antigenic and functional characteristics as we have ob-
served for DSCs and EnSCs [34, 37, 52, 59].
Endometriosis and Mesenchymal Stem/Stromal Cells
The relationship between EnSCs and MSCs may explain the
appearance of endometriosis foci in distant sites, such as the skin,
lung and brain, as well as cases of endometriosis in men, which
are not attributable to retrograde menstruation but to “erroneous
homing” of MSC-related precursors, which are transported by
Table 1 Characteristics of
decidual and endometrial stromal
cells
ANTIGEN PHENOTYPE References
CD45-, CD31-, CD3-, CD19-
Endometrial stomal cell marker: CD10+
MSC/pericytes markers: CD13+, CD44+, CD90+,
CD140b+, CD146+, α-SM actin+, nestin+,
STRO-1+
eMSC markers: CD140b+, CD146+, SUSD2+
Ruiz Magana, 2020 [34]
DECIDUALIZATION
Change from a fibroblastic to a rounder cell shape
Change from a perivascular location to a location
away from the blood vessels
Secretion of PRL, IGFBP-1 and IL-15







Dimitrov, 2010 [35]; Dimitrov, 2008 [36];
Munoz-Fernandez, 2018 [37]; Muñoz-Fernández,
2019 [38]; Ruiz Magana, 2020 [34]; Shokri, 2019
[39]
Hematopoietic cell supportive activity Alcayaga-Miranda, 2015 [40]; Blanco, 2009 [41]
Inhibition of NK cell cytotoxicity Croxatto, 2014 [42]; Shokri, 2019 [39]
Survival in xenotransplants Muñoz-Fernández, 2019 [38];Ye, 2018 [43]
Therapeutic effects on immune-based diseases Muñoz-Fernández, 2019 [38];Xu, 2018 [44]
PERICYTE CHARACTERISTICS
Perivascular location of preDSCs and preEnScs Ferenczy, 1983 [45]; Munoz-Fernandez, 2018 [37];
Wynn, 1974 [46]
Pericyte markers Munoz-Fernandez, 2018 [37]; Ruiz Magana, 2020 [34]
Expression of angiogenic factors Alcayaga-Miranda, 2015 [40]; Munoz-Fernandez,
2018 [37]
Cell contractility Kim, 2020 [47]; Munoz-Fernandez, 2018 [37]
Chemotactic activity Hirota, 2006 [48]; Munoz-Fernandez, 2018 [37]
Phagocytosis activity Cornillie, 1985 [49]; Ruiz, 1997 [50]
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the blood from the bone marrow to extraperitoneal tissues. In
addition, MSC-related precursors present in menstrual blood
may reach the peritoneum by retrograde menstruation [23, 35].
Nevertheless, endometriosis foci (both peritoneal and
extraperitoneal) contain both EnSCs and epithelial cells. These
two cell types may reflect either the existence of a common
precursor that gives rise to both epithelial and stromal cell line-
ages or to the existence of two independent precursors that de-
velop in the bone marrow and then colonize the endometrium.
Given these two possibilities, it is unlikely that two independent
precursors from the bone marrow can each erroneously colonize
an extraperitoneal tissue to produce extraperitoneal endometri-
osis foci. Thus, it is more likely that there is a single precursor
that gives rise to both epithelial and stromal cells. The fact that
both MSCs and EnSCs can differentiate into epithelial cells [58]
supports the existence of a single precursor related to MSCs and
EnSCs. This precursor may colonize the endometrium under
normal conditions where it differentiates into epithelial and stro-
mal cells. In endometriosis, the precursor may form both perito-
neal and extraperitoneal foci, which differentiate into both epi-
thelial and stromal cells. Similar to EnSCs and DSCs, bone mar-
row MSCs change from a fibroblastic to a rounder morphology
and express PRL mRNA in the presence of P4 and cAMP
(decidualization factors) in culture, but unlike EnSCs and
DSCs, MSCs are unable to secrete PRL [53]. A similar process
may occur in the case of eEnSCs, which undergo morphological
modifications and express PRL mRNA when decidualized but
are unable to secrete PRL [21]. These findings suggest that
eEnSCs are closer to MSCs than to EnSCs and DSCs, and they
also suggest that eEnSCs have lost, through a primary or induced
mechanism, the ability to progress toward decidualized EnSCs
[23].
Ectopic Tissues with Stromal and Immune Cells:
Endometriosis
We have observed phenotypic and functional relationships
between DSCs/EnSCs and stromal cells (SCs) in secondary
lymphoid organs (SLOs). These SCs also derive from MSCs
and contribute to lymphoid tissue organization by interacting
with immune cells in SLOs, attracting these cells by secreting
chemokines and inhibiting their apoptosis by producing anti-
apoptotic factors [60]. In addition to their similarity in antigen
phenotype with SCs, EnSCs and DSCs have chemotactic and
anti-apoptotic properties similar to those of SCs [53, 54, 59,
61]. Although the decidua and endometrium cannot be con-
sidered SLOs (because they lack the characteristic compart-
mentalization in T and B zones), they may be considered non-
lymphoid immune tissues equivalent to the skin. As shown for
SCs, EnSCs and DSCs may also participate in the organiza-
tion of the endometrium and decidua by attracting and
interacting with leukocytes. Another aspect shared by
EnSCs and SCs of SLOs is that both cell types have been
detected in ectopic locations associated with inflammatory
processes. Patients with rheumatoid arthritis frequently have
lymphoid tissue in the synovium (a tertiary lymphoid organ)
along with the presence of SCs [62]. Endometriosis may rep-
resent an equivalent ectopic situation for EnSCs despite the
finding that endometriomas contain eEnSCs and a significant
proportion of leukocytes, mainly macrophages [12, 13].
Similar to SCs, eEnSCs may attract leukocytes in ectopic
areas, thereby contributing to the development of
endometriomas.
Endometriosis as a Macrophage Disease
In a review of the involvement of macrophages in the patho-
genesis of endometriosis [62], the authors argue that macro-
phage recruitment into lesions is not only an early event in the
development of foci but is also a necessary step for the estab-
lishment of endometriotic lesions. Macrophages produce cy-
tokines, growth factors and angiogenic factors that affect
eEnSCs and contribute to the development of endometriomas.
In other words, endometriosis arises from the crosstalk be-
tween eEnSC and macrophages. Although M2 macrophages
have been observed in the peritoneum and in endometriosis
foci [63], there is no consensus regarding the type of macro-
phage involved in the process. One possibility is that M1
macrophages contribute to the inflammatory environment,
while M2 cells favor the angiogenesis that characterizes the
disease [64]. eEnSCs may secrete chemokines that attract
macrophages to the endometriosis foci. However, one of the
most important contributors in intercellular communication
are extracellular vesicles (EV) that transport molecules from
one cell or tissue to another. EVs perform their function by
interacting directly with receptors on the cell surface or by
delivering their contents to the target cell by endocytosis,
phagocytosis or membrane fusion. EVs contain a wide variety
of cytoskeletal, cytosolic, plasma membrane and heat shock
proteins. The presence of cytokines, miRNA and other
ncRNAs have also been reported. Recent work has document-
ed differences in the miRNA profile between exosomes re-
leased by EnSCs from patients with endometriosis and
exosomes from normal endometrium [65]. More recently,
work in a murine model of endometriosis has demonstrated
the ability of exosomes produced by eutopic endometrial cells
to regulate macrophage activity, favoring differentiation to
M2 cells and reducing their phagocytic capacity [66].
Current therapeutic strategies for endometriosis are based
primarily on hormone therapy. This treatment generates a
hypoestrogenic state that leads to numerous side effects sim-
ilar to those that occur during menopause, and it aggravates
existing infertility problems in these women. Moreover, the
success of this therapy depends on the location and type of
endometriotic lesion. In the search for new approaches for
treatment, a potentially informative avenue of study is to
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elucidate the molecular dialogue between eEnSCs and mac-
rophages during the development of endometriosis as well as
to identify the molecules that participate in this dialog to in-
vestigate the possibility of blocking them with antibodies or
chemokine receptor antagonists.
Epigenetic Modifications of Stem Cells
The unique nature of stem cells consists of three general prop-
erties as follows: capability of dividing and renewing them-
selves for long periods; unspecialization; and ability to differ-
entiate into specialized cell types [67]. To that end, metabo-
lism of stem cells and control of gene expression must be
precise with rapid adjustment to changing conditions (e.g.,
hormonal status and menstrual cycle phase), including envi-
ronmental factors [68, 69].
The control of gene expression has attracted the attention of
researchers due to the possible induction of molecular mech-
anisms, resulting in epigenetic DNA modifications that in-
volve changes in gene activity but not in DNA sequence
[69, 70]. Thus, an epigenome consists of all chemical modifi-
cations to the DNA (e.g., methylation) and histone proteins
(e.g., acetylation and succinylation) that regulate the expres-
sion of genes within the genome through chromatin conden-
sation but without changes in the DNA nucleotide sequence
[71]. Gene expression can be controlled through the action of
repressor proteins that attach to silencer regions of the DNA,
resulting in binding to mRNA and prevention of ribosome
assembly. Small non-coding RNA (micro)molecules
(miRNAs) containing approximately 20–22 nucleotides are
abundant in many mammalian cell types and silence
mRNAs by interfering with their translation. miRNA-
dependent RNA silencing and post-translational regulation
of gene expression occur through one or more of the following
processes: cleavage of the mRNA strand into two pieces; de-
stabilization of mRNA through shortening of its poly(A) tail;
and less efficient translation of mRNA into proteins by ribo-
somes [72, 73]. Epigenetic regulation by miRNA targets ap-
proximately 60% of human genes [74]. The main epigenetic
mechanisms and the most significant epigenetic factors are
presented in Fig. 2.
Even without altered DNA sequence that lasts for multiple
generations or only for the duration of the cell’s life, non-
genetic factors may cause the organism’s genes to behave
differently [75, 76]. Epigenetic change is a regular and natural
occurrence in response to aging, the environment/lifestyle and
disease state. This phenomenon is aimed to maintain genomic
integrity [75, 77]. Accordingly, epigenetic homeostasis failure
in the endometrial tissue may reflect local intrauterine abnor-
malities or generalized systemic pathology during repeated
menstrual cycles or pregnancies due to endogenous causes
(e.g., hormonal disorders) and/or exposure to some environ-
mental risk factors [24, 78].
Aim of Review
There has been increasing evidence in recent years that the
role of epigenetic mechanisms and processes in the pathogen-
esis of various disease conditions in humans have been
underestimated, including the unclear etiology of endometri-
osis [79–81].
In parallel with the progress in the understanding of mod-
ification of gene expression without changing DNA sequence,
abnormal differentiation of stem cells and their clonogenic
and/or proliferative activities have attracted the attention of
independent scientific teams as a significant cause of morbid-
ity and mortality [82]. It has been proposed that hormone-
mediated epigenetic modifications of the genome in EnSCs
or even MSCs play an important role in etiopathogenesis of
endometriosis [83]. The roles of excess estrogen and P4 resis-
tance are crucial [19].
Thus, the aim of this review was to combine the current
knowledge of the epigenetic background of EnSCs andMSCs
and the changed properties due to estrogen/P4 imbalances in
the context of etiopathogenesis of endometriosis.
Main Female Sex Hormones and Epigenetic
Modifications of EnSCs and/or MSCs
in Endometriosis
Hormone release dynamics govern periodic growth and re-
gression of the endometrium, creating an extraordinary model
for controlled tissue remodeling. Following the implantation
theory of endometriosis that assumes the possibility of EnSCs
spreading out with the menstrual blood, the interplay between
sex steroid hormones throughout the menstrual cycle and the
expression of their receptors deserves attention.Moreover, the
nature of endometriosis is estrogen-dependent and P4-
resistant [83, 84]. Thus, significant changes in the functional
characteristic of EnSCs may result from epigenetic aberration
of the expression of respective genes, especially genes linked
to estrogens and P4 activities [85, 86].
Estrogen Production and Metabolism
Both eutopic endometrium and ectopic endometrial foci are
the main target tissues for estrogens, the primary female sex
hormones [84]. At this point, it is worth noting that endome-
trial or endometriotic intratissue estrogen concentrations do
not reflect the corresponding serum levels. Absolute or rela-
tive excess of estrogens has been reported in endometriosis,
especially local within the lesions [87]. Estrogen-dependent
endometriosis is rarely diagnosed after menopause when the
symptoms and endometriotic lesions are typically relieved
[88]. Analogical reduction of the estrogen effect during preg-
nancy (overbalanced by P4) or pharmacological suppression
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of endogenous estrogen synthesis (e.g., by use of
ethinylestradiol-containing combined oral contraceptive pills)
are likely to diminish intensity of the disease [89, 90].
The member of the cytochrome P450 family (CYP) and the
product of the CYP19A1 gene, aromatase (EC 1.14.14.1),
also known as estrogen synthetase or estrogen synthase, is a
unique rate-limiting enzyme in the biosynthesis of estrogens
from androgen precursors. The androgenic substrates for aro-
ma tase , and ros t ened ione , t e s tos t e rone and 16-
hydroxytestosterone are converted into the following respec-
tive estrogens: estrone (E1), estradiol (E2; the most potent) and
estriol (E3) [91]. Estradiol is an extremely strong mitogen for
endometriotic tissue. Therefore, it is reasonable to assume that
any alterations in aromatase activity will produce a shift in the
balance between estrogenic and androgenic effects within the
responsive tissues. Interestingly, it has been reported that
growth of ectopic endometrial tissue requires high aromatase
activity induction, which is normally not detectable in eutopic
endometrium [92]. In contrast to endometriosis tissue, estro-
gens are not locally produced in endometrium. EnSCs pro-
duce estrogens, and the presence of P450 aromatase mRNA
has been observed in EnSCs obtained from women with pel-
vic endometriosis [93]. Similar to breast cancer, aberrantly
expressed aromatase in endometriotic stromal cells is stimu-
lated by one of the best-knownmediators of inflammation and
pain, prostaglandin E2 (PGE2), via the promoter II region of
the aromatase gene, resulting in local production of estrogen.
Because estrogen itself upregulates cyclooxygenase 2 (COX-
2) and therefore stimulates PGE2 formation, a positive feed-
back cycle is established [91–93].
There is evidence that a hyperestrogenic microenvironment
within endometriotic lesions is a consequence of an epigenetic
regulatory mechanism involving the aromatase gene located
on chromosome 15q21. Multiple exons of this gene
(CYP19A1) are potentially compatible with unique promotors
that are present within the surroundings [94]. Alternative use
of these exons ensures a precisely adjusted level of aromatase
expression in the respective tissues. Endometriotic cells cor-
responding to EnSCs exploit identical aromatase promoters
(promoters II, I.3 and I.6) as aromatase-free eutopic endome-
trial cells [95]. Considering that the endometriotic stromal
cells share the same promoters with eutopic endometrial stro-
mal cells, different expression of the aromatase gene indicates
that an epigenetic regulatory mechanism inhibits this enzyme
gene expression in healthy endometrium, whereas this effect
is not present in endometriosis. CpG islands, the regions of the
genome rich in promoters, are hypomethylated in
endometriotic cells and hypermethylated in endometrial cells
[96]. In particular, the differential expression of aromatase
between eutopic normal endometrium and endometriotic foci
may be due to the absence or presence, respectively, of the
transcription factor, steroidogenic factor 1 (SF-1). In fact,
methylation of CpG islands in the SF-1 gene, which spans
from exon II to intron III, positively regulates its expression
in stromal cells present in endometriosis, whereas hypomethy-
lation of SF-1 gene CpG islands in normal endometrium is
associated with drastically lower SF-1 levels [97, 98].
Another abnormality pertaining to the estrogenic hyperac-
tivity reported in endometriosis is caused by deficient 17β-
hydroxysteroid dehydrogenase type 2 (17β-HSD2) expres-
sion. Physiologically, the conversion of adequate levels of
17β-estradiol to much less potent estrone is required to pre-
vent accumulation of increasing quantities of estradiol in tar-
get tissues, including endometroid foci [99]. Such inactivation
of 17β-estradiol is also regulated by DNA methylation, and it
has been demonstrated that hypermethylation of the 17β-
HSD2 gene body in ectopic stromal cells blocks the enzyme
activity [100]. As mentioned above (see Chapter 1.3), DNA
methylation is strictly linked to histone modifications and re-
cruitment of histone deacetylases (HDACs) followed by chro-
matin condensation. The same epigenetic process (e.g., DNA
methylation) is likely to influence activity of 17β-
hydroxysteroid dehydrogenases type 1 and 4 (17β-HSD1
and 17β-HSD4, respectively), which are enzymes present in
Fig. 2 Main epigenetic mechanisms – an overview. Important factors influencing epigenetic activities and possible health consequences are also
depicted
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the human endometrium and EnSCs [101, 102]. The above
interactions between estrogens and epigenetic modulators of
estrogen signaling at the level of endometrial foci versus nor-
mal eutopic endometrium are shown in Fig. 3.
Estrogen Receptors (ERs) and Estrogen-Mediated Control
of Epigenetic Mechanisms
Endometrial cells corresponding to MBSCs/MSCs and
displaying stem cell markers, such as Oct-4, SSEA-4, Nanog
and c-kit (CD117), simultaneously show expression of bothmain
estrogen receptor isoforms (ERα and ERβ) and G protein-
coupled estrogen receptor 1 (GPER), a member of the G
protein-coupled receptor (GPCR) family [9, 10, 84, 103].
These ER subtypes are encoded by separate genes. Estrogen
signaling is selectively regulated by the relative balance between
ERα and ERβ expression in target organs. Although both ERα
and ERβ are present in the endometrium, ERα is the primary
mediator of the estrogenic action in this tissue [104]. Encoded by
theGPER gene, the GPER protein is amember of the rhodopsin-
like family of G protein-coupled receptors and is a multi-pass
membrane protein that localizes (unlike the other members of the
GPCR family) predominantly to the endoplasmic reticulum.
GPER binds E2, resulting inmobilization of intracellular calcium
and synthesis of phosphatidylinositol (3,4,5)-trisphosphate
(PIP3) in the nucleus. Therefore, GPER is responsible for some
of the rapid nongenomic effects that E2 exerts on cells [105]. It
has been reported that GPER is significantly upregulated in en-
dometriosis and during carcinogenesis, whereas epigenetic
downregulation of GPER functions as a tumor suppressor in
colorectal cancer [10, 106, 107].
There is no reason to assume that epigenetic regulation of
estrogen receptors in EnSCs significantly differs from that
observed in other estrogen-reactive tissues [98, 108, 109].
For instance, independent researchers have reported markedly
higher levels of ERβ and lowered levels of ERα in human
endometriotic stromal cells corresponding to EnSCs com-
pared with EnSCs within eutopic endometrial tissues [110,
111]. These disorders have been linked to abnormally lowered
methylation of a CpG island in the promoter region of the
ERβ gene (ESR2) in endometriosis, resulting in ERβ overex-
pression. Bisulfite sequencing of this region has shown sig-
nificantly higher methylation in primary endometrial cells ver-
sus endometriotic cells [112]. Moreover, treatment with a
demethylating agent significantly increases ERβ mRNA
levels in endometrial cells. High levels of ERβ, in turn, sup-
press ERα expression and response to E2 in endometriotic
stromal cells via binding to non-classical DNA motifs in al-
ternatively used ERα promoters [9]. Both in vitro and in vivo
studies have confirmed induction of ERα expression in re-
sponse to E2 in human endometrial stromal cells. However,
in endometriotic foci, abnormally high quantities of E2
resulting from the local aromatase overactivity in addition to
epigenetic upregulation of ERβ in stromal cells may suppress
the normal response pertaining to ERα expression [113].
Lowered expression of ERα observed in endometriosis may
predispose to insufficient responsiveness to E2 with respect to
progesterone receptor (PR) expression, thus contributing to
Fig. 3 Interactions between estrogens and epigenetic modulators of
estrogen signaling in endometriosis (see main text for details). ① - defi-
cient 17β-hydroxysteroid dehydrogenases expression due to hyperme-
thylation of the respective genes; ② - estrogenic hyperactivity caused
by methylation of CpG island in the SF-1 gene; ③ - aromatase gene
activation due to CpG islands hypomethylation; ④ - positive feedback:
Estrogens→ COX-2 → PGE2→ aromatase activity. COX-2 – cycloox-
ygenase 2; CYP19A1 gene – gene coding aromatase (EC 1.14.14.1);
MBSC – menstrual blood stem cells; PGE2 – prostaglandin E2; SF-1 –
transcription factor steroidogenic factor 1
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secondary PR deficiency and P4 resistance, which is typically
observed in women with this disorder [9, 85]. Considering
that ERβ also regulates cell cycle progression, another con-
tributing factor to proliferation of endometriotic foci should be
expected [114]. Thus, alteration in DNA methylation may be
included in the pathomechanism responsible for severely in-
creased ERβ mRNA levels in EnSC- and/or MSC-derived
endometriotic cells.
Another epigenetic mechanism that may explain extraordi-
narily higher ERβ and significantly lower ERα and PR levels
in endometriotic stromal cells compared with endometrial
stromal cells is connected to miRNAs. The Human Genome
Project has demonstrated that approximately 80% of our DNA
is transcribed in RNA molecules but that only 2% of the ge-
nome is translated into proteins [115]. The majority of the
remaining RNA does not code for proteins but is processed
to produce functional RNAs. One of the most intensively
studied groups of non-coding RNAs is miRNAs. miRNAs
are crucial regulators of gene expression in E2-treated human
endothelial cells [116]. Similarly, studies using animal models
and humans have confirmed the significant role played by
miRNAs in endometrial physiology and pathology by modu-
lating the levels of estrogen receptor expression during the
different phases of the menstrual (endometrial) cycle [115,
117]. It has been reported that numerous miRNAs directly
target ERα, but less information is available for miRNAs
modulating ERβ and GPER [118–121]. However, it has been
recently demonstrated that GPER-mediated downregulation
of miR-148a expression through the GPER/miR-148a/HLA-
G signaling pathway may mediate the development of ovarian
endometriosis [122].
Interestingly, the effect of direct regulation of ER expres-
sion by miRNAs is to some extent balanced by the following
coexisting opposite mechanism: ER-mediated regulation of
miRNA expression. A recent study has shown that E2-treated
human umbilical vein endothelial cells (HUVECs) have dif-
ferentially regulated specific miRNAs via pathways related to
both classical ERs (ERα and ERβ) andmembrane-bound ERs
(GPER) [116]. Among the most modified miRNA, miR-30b-
5p, miR-487a-5p, miR-4710 and miR-501-3p were over-
expressed after E2 treatment, while miR-378 h and miR-
1244 were down-regulated [116]. Analysis of the identified
miRNAs indicates that these two mechanisms (regulation of
ER expression bymiRNAs vs. regulation of miRNAs by ERs)
act in a parallel manner.
In addition to miRNAs, some transcripts longer than 200
nucleotides lacking protein coding potential and transcribed
by the RNA polymerase II (RNA Pol II), which are known as
long non-coding RNAs (lncRNAs), may affect estrogen sig-
naling by regulating the epigenetic status of protein-coding
genes [123]. Together with the research progress on
lncRNAs, there is increasing evidence that lncRNAs are in-
volved in the pathogenesis of endometriosis [124]. For
example, the lncRNA, HOTAIR, is upregulated by estradiol
binding to the estrogen receptors, ERα and ERβ. Co-regula-
tors, including histone methyltransferases (MLL1 and MLL3)
and histone acetylases in the p300–CBP family, are recruited
together with estrogen receptors to bind estrogen response
elements in the HOTAIR promoter in response to 17β-
estradiol treatment, and they are necessary for the upregula-
tion of HOTAIR [125]. The above interactions leading to
dysregulated estrogen receptor expression in endometriosis
are shown together with comodulators of estrogen signaling
in Fig. 4.
Comodulators of Estrogen Signaling
Estrogen signaling involves recruitment of many
comodulators (coactivators and corepressors) that interact
with manymembers of the nuclear receptor-related multifunc-
tional protein complexes, resulting in both transcriptional and
epigenetic changes. The latter include chromatin density
changes, histone modifications by acetylation/deacetylation
and DNA methylation/demethylation. Thus, modulation of
gene expression in EnSCs/MSCs depends on recruitment of
comodulators crucial for the activities of the respective acetyl-
transferases (e.g., p300-CBP and its paralog p300; GNAT or
GCN5-related N-acetyltransferase, nuclear receptor
coactivator-NCOA-related histone acetyltransferase) and
methyltransferases (e.g., histone-lysine N-methyl-
transferases and histone-arginine N-methyltransferases)
[127–129].
Interestingly, steroid receptor RNA activator (SRA) is a
type of lncRNA that coordinates the functions of various tran-
scription factors and enhances steroid receptor-dependent
gene expression. As a nuclear receptor coactivator, SRA can
coactivate both ERα and ERβ [130]. Low expression levels
of SRA lncRNA and ERα but relatively high expression
levels of SRA and ERβ have been detected in ovarian
endometriotic tissues compared to normal endometrial tissues.
Moreover, SRA1-small interfering RNA treatment signifi-
cantly increases ERα levels but reduces ERβ levels in
EnSCs. Treatment with interfering RNA also attenuates pro-
liferation of ovarian endometriotic cells and promotes early
apoptosis in these cells [131].
Sirtuins (SIRTs) possessing histone deacetylase (HDAC)
activities are a good example of gene silencing by
comodulators. For instance, SIRT1 represses estrogen-
regulated gene expression and inhibits ligand-dependent acti-
vation of ERα [132]. Overexpression of SIRT1 may contrib-
ute to both the pathogenesis of endometriosis and P4 resis-
tance (Fig. 4.) [133]. Interestingly, examination of eutopic end
ectopic endometrial tissue obtained from the same patient has
shown significantly decreased levels of SIRT1 mRNA in
eutopic EnSCs compared to fEnSCs [134].
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Thus, at different stages, complex and non-uniform mech-
anisms of estrogen/ER signaling within endometrial cells are
subjected to significant modulation by epigenetic factors.
Disruption of this modulation may explain the ectopic in-
crease of EnSCs/MSCs with formation of endometriotic foci
[135–138].
P4 Signaling
Many different authors share the view that there is a pivotal
role in the pathogenesis of endometriosis associated with en-
dometrial resistance to P4 (Fig. 5.) [21, 85]. Studies of normal
human endometrial tissue comprising mesenchymal stem/
stromal cells and/or endometrial stromal cells (MSCs/
EnSCs) have demonstrated that prior exposure to P4 not only
downregulates matrix metalloproteinase (MMP) expression
but also limits the ability of locally produced proinflammatory
cytokines to stimulate the expression of these enzymes. In
contrast, endometrial tissues from women with endometriosis
demonstrate an altered response to P4, allowing continuous
expression of MMPs throughout the secretory phase [139].
Genomic activity related to the action of P4 in target tissues
is normally mediated by nuclear progesterone receptor (PR).
PR is expressed as two primarily functionally distinct iso-
forms, PR-A and PR-B, which are encoded by the same gene
on chromosome 11q22-q23; however, they are transcribed
from two distinct promoters [140, 141]. The isoforms PR-A
and PR-B differ only in that human PR-B contains an addi-
tional 164 amino acid far N-terminal region called the “B-
upstream segment” (BUS), which confers activation function
3 (AF3) activity [140]. Whereas the PR-B isoform was shown
to stimulate transcriptional activity orchestrated by P4, lacking
the BUS in the PR-A isoform predisposes patients to act as a
dominant repressor of PR-B in many target tissues, including
the endometrium [140]. Therefore, PR-B promotes uterine
epithelial proliferation when not repressed by PR-A [142].
Consequently, in addition to functional abnormalities of the
existing PRs, an altered PR-A/PR-B ratio might render specif-
ic target tissues responsive or resistant to P4, which could be
essential for the pathogenesis and inflammatory activity of
endometriosis. Both PR-B deficiency and PR-A overexpres-
sion should be considered [143]. For example, a decreased
PR-B/PR-A ratio was demonstrated in endometrial cells after
pretreatment with either tumor necrosis factor-alpha (TNF-α)
and in peritoneal fluid obtained from women with advanced-
stage endometriosis [143]. Therefore, P4 plays a crucial role in
endometrial receptivity by acting through PR isoforms PR-A
and PR-B. Further, in a role that may be essential for fertility,
both PR isoforms regulate decidual prolactin (PRL) expres-
sion - a marker of decidualization - in differentiating human
endometrial stromal cells [144]. DNA methylation and post-
transcriptional silencing of target genes by miRNAs are two
important epigenetic mechanisms regulating receptivity with-
in eutopic endometrial tissue. It was demonstrated that both
Fig. 4 Normal vs. deranged estrogen receptors expression due to
influence of epigenetic mechanisms: normal eutopic endometrium vs.
endometriotic foci (see main text for details). Pathomechanism of P4
resistance is also depicted. ① - suppression of ERα expression in re-
sponse to E2 via binding to non-classical DNA motifs in alternatively
used ERα promoters; ② - decreased ERα expression-caused secondary
PR deficiency leads to P4 resistance. ERα, ERβ – estrogen receptor α
and β, respectively; ESR2 gene – ERα gene; GPER – G protein-coupled
estrogen receptor 1; PR – progesterone receptor; SIRT1 – sirtuin 1. *
Experimentally validated miRNAs that directly regulate ER gene
expression microRNAs include miR-148a, miR-18a, miR-18b, miR-
19a, miR-19b, miR-20b, miR-22, miR-130a, miR-193b, miR-206, miR-
221, miR-222, miR-302c, let-7a, let-7b, let-7i, miR-92 [108, 122]; ER-
mediated regulation of miRNA expression includes miR-30b-5p, miR-
487a-5p, miR-4710, miR-501-3p, miR-378 h, miR-1244 [116]. # List of
dysregulated ERs-associated lncRNAs detected in humans includes
TMPO-AS1, LINC01116, H19, LASER1, MIR2052HG, LINC00707,
LncRNA-Glu, LINC00472, LncRNA-RoR, NEAT1, MTA1,
LncSHGL, HOTAIR [126]
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P4 synthesis and the expression of PR-A/PR-B in MSCs and
EnSCs are epigenetically regulated by DNA methylation
[145, 146]. Furthermore, studies in a primate (baboon) model
for endometriosis revealed that P4 resistance in endometriosis
is modulated by the altered expression of miRNA-29c and
changes in the levels of its target transcript, FK506-binding
protein 4 (FKBP4) [147]. Following induction of endometri-
osis in baboons, the mean expression of miRNA-29c in the
eutopic endometrium was increased with a coexisting de-
crease in FKBP4 level in this tissue. Human data corroborated
the baboon data and demonstrated significantly higher expres-
sion of miRNA-29c in the eutopic endometrium of women
with endometriosis than what was observed in the normal
endometrium of controls. Moreover, after radical laparoscopic
excision of endometriosis, miRNA-29c expression in the
eutopic endometrium of female patients was markedly de-
creased compared with the levels in preoperative eutopic tis-
sue samples containing MSCs/ EnSCs. FKBP4 showed an
inverse trend postoperatively [147]. In another study, the re-
lationship between miRNA-196a levels and PR expression
was studied in the context of the Ras/Raf/MEK/extracellular
signal-regulated kinase (ERK) signaling pathway [148]. It
was demonstrated that upregulation of MEK/ERK signaling
by miRNA-196a is involved in epigenetic downregulation of
PR in the eutopic endometrium of women with endometriosis
[148]. It is very likely that other miRNAs not yet known may
also be responsible for progestin resistance in endometriosis.
The combination of local (ectopic) growth and inflamma-
tion is the immanent feature of endometriosis, producing a
vicious circle with further promotion of proliferation and more
inflammation if not successfully treated. Considering that the
prolonged stimulation by a pro-inflammatory cytokine (e.g.,
NF-κB) induces at least partial methylation at PR-B with con-
comitant PR-B downregulation in endometriotic cells, the ef-
fects of such epigenetic exclusion of local P4 receptivity may
be crucial in the pathophysiology of endometriosis. A study
on an immortalized endometrial stromal cell line derived from
a normal woman revealed that the knockdown of PR-B by a
small interfering RNA (siRNA) leads to a significant increase
in proliferation [149, 150]. Being aware of the limitations of
this in vitro study, the results suggested that PR-B knockdown
might be responsible, at least in part, for increased prolifera-
tion and resistance to apoptosis, as seen in the eutopic and
ectopic endometrium of women with endometriosis [150].
There are non-answered questions about the relationship be-
tween eutopic endometrium and ectopic endometrial foci
Fig. 5 Epigenetic contributions to P4 signaling in the context of P4
resistance in endometriosis: normal eutopic endometrium vs
endometrial tissues from women with endometriosis (see main text for
details). DNAm – DNA methylation; EGF – epidermal growth factor;
EMX2 – homeobox protein EMX2 (Empty Spiracles Homeobox 2);
FKBP4 – FK506-binding protein 4, target transcript of miRNA-29c;
FOXA2, FOXO1A – transcription factors; HOXA1, HOXA11 –
homeobox proteins; IGFBP-1 – insulin-like growth factor binding pro-
tein 1; MEK/ERK – the Ras/Raf/MEK/extracellular signal-regulated ki-
nase (ERK) signaling pathway; MIG6 – mitogen inducible gene 6; MMP
– matrix metalloproteinase; P4 – progesterone; PGRMC1, PGRMC2 –
progesterone receptor membrane components 1 and 2, respectively; PR-
A, PR-B, mPRs – progesterone receptors: A, B and membrane-bound,
respectively
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regarding the trigger of P4-attenuated response or P4 resistance.
It is still not clearly demonstrated how a defective endometrium
could initiate the conditions that predispose patients to endome-
triosis or, alternatively, whether endometriosis produces ham-
pered endometrial receptivity to P4 [21, 151]. It was proposed
that the eutopic endometrium of ill women had an attenuated
response to P4 because estrogen-responsive genes are not sup-
pressed in their stromal cells compared to normal women in the
early secretory phase of the menstrual cycle, which would sug-
gest a phenotype of P4 resistance [152]. A potential mechanism
responsible for the altered expression of the respective genes
linked to decreased endometrial receptivity in endometriosis
was demonstrated in an animal model. Based on mouse compar-
ative studies, it was suggested that impaired endometrial recep-
tivity in the endometriosis group may be caused by altered gene
expression due to methylation of the homeobox protein A10
(HOXA10) and A11 (HOXA11) [151]. Hoxa10/HOXA10 and
hoxa11/HOXA11 are important transcriptional moderators that
either activate or repress the downstream target genes involved in
uterine embryogenesis and endometrial receptivity [153]. During
the normal menstrual cycle in women, the expression of both
HOXA10 and HOXA11 is driven by sex steroids, peaks rapidly
during the implantation window in response to rising P4 levels,
and then remains elevated throughout the secretory phase [154].
This increase in HOXA10 and HOXA11 levels is not observed
in patients with endometriosis [155, 156]. Considering that en-
dogenous endometrial HOXA10 expression directly regulates
endometrial expression of important factors for embryo implan-
tation, including β3-integrin and the divergent homeobox gene
emx2/EMX2, hypermethylation of hoxa10 at the peri-
implantation period may predispose patients to epigenetically
determined infertility [153]. Indeed, silencing hoxa10 via meth-
ylation counteracts EMX2 downregulation, and abnormally high
levels of EMX2 expression were demonstrated in endometriosis.
Next, the β3-integrin subunit, as a direct hoxa10 downstream
target gene, was aberrantly expressed at low levels at the time
of implantation in the endometrium of women with endometri-
osis [157, 158]. Moreover, methylation of hoxa10 and hoxa11
leads to the release of blocked expression of proinflammatory
cytokines; one such group, is the interleukin-1 (IL-1) family, a
group of 11 cytokines that plays a crucial role in the regulation of
immune and inflammatory responses (including the conceptus-
endometrium interaction) to establish pregnancy [159, 160]. It
follows from the above data that altered PR expression or dimin-
ished activity identified in endometriosis as P4 resistance may be
caused by aberrant epigenetic regulation of P4-responsive genes
(including hoxa10 and hoxa11) in eutopic EnSCs. In turn, other
mediators of endometrial receptivity that are regulated by hox
genes, such as pinopodes, alphavbeta3 integrin, and IGFBP-1,
are downregulated in endometriosis [154]. The relatively perma-
nent nature of P4 target gene silencing by methylation may ex-
plain the typically observed but unsatisfactory treatments for
endometriosis-related infertility [154].
According to recent studies, epigenetic modifications of
another P4-regulated gene in the eutopic endometrium of
endometriosis-affected individuals may be crucial in P4 re-
sistance and disease etiology. These modifications include
DNA hypermethylation with altered gene expression rele-
vant to endometrial function/dysfunction, including cell mi-
gration and proliferation [161]. Functional loss of the re-
spective chromosomal regions due to hypermethylation
resulting in downregulation of proteins that regulate the cell
cycle in the endometrial tissue of women with endometri-
osis, such as transcription factors FOXO1A and FOXA2,
protein ErbB-2 (TOB1) and mitogen inducible gene 6
(MIG6), has been well documented [98, 162, 163]. The
latter is a negative regulator of epidermal growth factor
(EGF), and it promotes proliferation and migration of
EnSCs [164, 165]. Similarly, FOXA2 deficiency was found
to contribute to cell proliferation and migration in eutopic
endometrium from patients with endometriosis. Thus, these
women may participate in the “metastatic” process of
eutopic endometrium transitioning into ectopic loci.
Unlike in endometriosis, FOXA2 expression can be in-
duced by P4 in a healthy endometrium [166].
The discovery of membrane-bound progesterone receptors
(mPRs: mPRα–ϵ) of the progestin and adipoQ receptor
(PAQR) family, including progesterone receptor membrane
component 1 and 2 (PGRMC1 and PGRMC2), suggests that
7-transmembrane receptors coupled to G proteins may be in-
volved in fast cell surface-initiated actions by P4 that – unlike
the actions of P4 via classical PRs – occur over a time scale of
minutes [167–169]. It was demonstrated that changes in the
balance between PGRMC1 and PGRMC2 may participate in
and/or regulate EnSCs survival (mitosis and apoptosis)
throughout the menstrual cycle [170].
There is increasing evidence that PGRMC2 facilitates pro-
gestational effects within the endometrial glands. Thus, abnor-
mal expression and/or intracellular localization of PGRMC2
may contribute to the blunted response to P4, leading to ab-
normal endometrial function and decreased fertility observed
in subjects with endometriosis. Indeed, reduced levels and
abnormal intracellular localization patterns of PGRMC2 in
the endometrium of primates (macaques) afflicted with ad-
vanced endometriosis were also observed [171]. This may
suggest that endometrial alterations in membrane-bound
PGRMC2 may contribute to the phenomenon of P4 resis-
tance. Similarly, altered expression of mPRs in MSCs and
EnSCs may be linked to infertility and endometriosis. The
expression of the progesterone membrane receptor (mPR-β)
in the endometrial tissue of patients with recurrent spontane-
ous abortions was significantly lower in comparison with that
of the normal control group, whereas endometrial PGRMC-1
and PGRMC-2 expression was reported to be downregulated
in secretory phase endometrium from women with advanced
stage endometriosis [172, 173].
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Increasing evidence suggests that intracellular signaling
pathways related to mPR involve rapid nongenomic actions
that may be epigenetically controlled throughout the menstru-
al cycle [174, 175]. It has been proven that a mitogen-
activated protein kinase (MAPK), a key enzyme in mPR sig-
nal transduction pathway (the Ras-Raf-MEK-ERK pathway)
affects chromatin modifications in multiple ways producing
histone modifications through phosphorylation of transcrip-
tion factors including the cAMP-response-element binding
factor (CREB) and NF-κB, which recruit chromatin-
modifying complexes and through direct phosphorylation of
histones [176–178]. However, further in vivo experiments
with specific mPR agonists and antagonists are needed to
elucidate the strength of these epigenetic influences in the
context of both the pathogenesis of endometriosis and new
treatment methods. The mentioned epigenetic contributions
to P4 signaling in the context of endometriosis are summa-
rized in Fig. 5.
Concluding Remarks
Knowledge about epigenetic mechanisms has significantly
increased in recent years. This also applies to endometriosis,
in which general endocrine mechanisms have been described
several decades ago but still without clarification of the trig-
gering factors [179]. There is currently no doubt that modifi-
cations ofMSCs and/or EnSCs that comprise histone variants,
posttranslational modifications of amino acids on the amino-
terminal tail histones and covalent modifications of DNA ba-
ses are involved in the etiopathogenesis of endometriosis or at
least significantly affect the course of endometriosis [78, 138,
180, 181]. Epigenetic alterations of the transcription factors of
estrogen and P4 signaling pathways in MSCs are robust in
endometriotic tissue [182]. Moreover, these processes leading
to P4 resistance and ER subtypes imbalances are not limited to
nuclear PRs and ERs but also include membrane-bound PR
and G protein-coupled ER 1 [176, 183]. Current therapies for
endometriosis cannot completely cure the disease, and pa-
tients present with high recurrence rates. Therefore, novel
medical approaches are needed. Perspectives for the future
may include MSCs and EnSCs as the potential targets of epi-
genetic therapies in the prevention and treatment of endome-
triosis [78, 184]. Potential advantages of single cell molecular
profiling in endometrium and in endometriotic foci should be
considered [184]. Moreover, in cases of higher invasiveness
of MSCs and/or EnSCs in ectopic locations, manifested in
higher proliferation, migration and angiogenic ability in com-
parison with eutopic MSCs/EnSCs, a tyrosine kinase inhibi-
tors may be promising. These compounds are able to revert
the increased proliferative, migratory and angiogenic
phenotype of ectopic endometrial MSCs [185]. Considering
that MSCs-related angiogenesis play important role in the
survival and proliferation of both eutopic and ectopic endo-
metrial tissue, inhibition of the formation of new blood vessels
represents a rationale for targeted antiangiogenic approach in
the treatment of endometriosis [186].
In addition, as only differentiated endometrial cells, and not
endometrial MSCs, possess fully expressed steroid hormone
receptors, the effectiveness of hypoestrogenism-inducing
therapies may depend on the number of EnSCs in menstrual
blood and/or cyclic mobilization of bonemarrow derived stem
cells (MSCs) [186]. Epigenetic modifications of gene expres-
sion regulation by dissecting the respective interactions be-
tween environmental factors and histone modification, DNA
methylation or miRNA and lncRNA expressions influencing
estrogen and P4 signaling may be crucial in developing new
remedies for endometriosis [187]. Thus, therapeutic modula-
tion of epigenetic drivers (epigenetic effectors) of endometri-
osis should be considered. However, ensuring the safety of
such treatment for the patient remains a task for the future
[187].
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